Goodwin advised RA Capital and Versant Ventures as joint lead investors on a €66 million Series A financing round for German T-knife GmbH. The round took place also with significant participation from the existing investors Andera Partners and Boehringer Ingelheim Venture Fund (BIVF).
T-knife is a next-generation adoptive T-cell company utilizing its proprietary humanized T-cell receptor (HuTCR) mouse platform technology to treat solid tumors. The company was spun out of Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin in 2018.
RA Capital Management headquartered in Boston is a multi-stage investment manager with a focus on healthcare and life sciences.
Versant Ventures is a leading healthcare investment firm headquartered in San Francisco with $2.4 billion under management.